Home > Haematology > ASH 2021 > Haemophilia > ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors

ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors

Presented By
Dr Guy Young, University of Southern California, CA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 3, ATLAS-INH
Treatment with fitusiran prophylaxis led to a lower rate of bleeding events and an improved health-related quality of life in patients with haemophilia A or B with inhibitors. The observed safety profile of fitusiran in the phase 3 ATLAS-INH trial was favourable and consistent with previous phase 1 and 2 studies in patients with severe haemophilia [1]. “Patients with severe haemophilia can develop inhibitors against factor VIII or IX, preventing factor replacement therapy from working,” said Dr Guy Young (University of Southern California, CA, USA). “A quarter of patients develops these inhibitors, leading to a worse prognosis. Novel agents are needed to protect these patients from bleeding events and arthropathy, and improve their quality of life. In addition, the current IV therapies need to be administered multiple times per week, resulting in venous access issues and poor adherence.” Fitusiran is an investigational, subcutaneous, small interference RNA...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on